You are here » Home » Companies » Company Overview » Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd.

BSE: 533573 Sector: Health care
NSE: APLLTD ISIN Code: INE901L01018
BSE LIVE 15:40 | 20 Jul 558.10 14.85
(2.73%)
OPEN

551.10

HIGH

573.55

LOW

539.95

NSE 15:41 | 20 Jul 559.45 14.50
(2.66%)
OPEN

547.95

HIGH

578.00

LOW

537.95

OPEN 551.10
PREVIOUS CLOSE 543.25
VOLUME 60807
52-Week high 709.30
52-Week low 492.25
P/E 25.33
Mkt Cap.(Rs cr) 10,520
Buy Price 0.00
Buy Qty 0.00
Sell Price 556.90
Sell Qty 5.00
OPEN 551.10
CLOSE 543.25
VOLUME 60807
52-Week high 709.30
52-Week low 492.25
P/E 25.33
Mkt Cap.(Rs cr) 10,520
Buy Price 0.00
Buy Qty 0.00
Sell Price 556.90
Sell Qty 5.00

Alembic Pharmaceuticals Ltd. (APLLTD) - Company History

Alembic Pharmaceuticals Ltd was incorporated on June 16 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in Pharamceulicals business. As per the scheme of arrangement the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date April 1 2010. In April 15 2011 the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 133515914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement the shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus the company became an associate of Alembic Ltd.In September 20 2011 the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange.During 2012 Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals Inc USA.During 2013 the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA.During 2014 the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A..During 2015 the companies associate signs exclusive agreement with Novartis.